In-Silico Investigation of Osimertinib Based Compounds as Potential Double Mutant EGFR Kinase Inhibitors Against H1975 Cell Line: Integrating QSAR Modeling, Molecular Docking, MD Simulations, and ADME/Tox Studies-Reference-Cited by-同舟云学术

In-Silico Investigation of Osimertinib Based Compounds as Potential Double Mutant EGFR Kinase Inhibitors Against H1975 Cell Line: Integrating QSAR Modeling, Molecular Docking, MD Simulations, and ADME/Tox Studies

Published:2023-08-11 Issue:1 Volume:7 Page:111-129
ISSN:2522-5758
Container-title:Chemistry Africa
language:en
Short-container-title:Chemistry Africa

Author:

El Bahi Salma,Boutalaka Meryem,Alaqarbeh Marwa^ORCID,El Alaouy Moulay Ahfid,Koubi Yassine,El Khatabi Khalil,Choukrad M.’barek,Sbai Abdelouahid,Bouachrine Mohammed,Lakhlifi Tahar

Publisher

Springer Science and Business Media LLC

Subject

Physical and Theoretical Chemistry,Environmental Chemistry,Chemistry (miscellaneous),Catalysis

Link

https://link.springer.com/content/pdf/10.1007/s42250-023-00744-x.pdf

Reference43 articles.

1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388. https://doi.org/10.1056/NEJMoa0909530

2. Wang Y, Schmid-Bindert G, Zhou C (2012) Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Ther Adv Med Oncol 4(1):19–29. https://doi.org/10.1177/1758834011427927

3. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462(7276):1070–1074. https://doi.org/10.1038/nature08622

4. Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, Martin TS, Karp R, Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Allen A (2013) Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M mediated resistance in NSCLC. Cancer Discov 3:1404–1415. https://doi.org/10.1158/2159-8290.CD-13-0314

5. Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Brad-bury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt PGL (2014) Wrigley Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 57:8249–8267